Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice.
Aged-mouse wound-repair experiments; not treated patients.
Reported findings. The synthetic actin-binding-domain peptide promoted dermal wound repair in aged mice.
Nonresponse. Fragment-specific nonresponse endpoints were not established in the accessible abstract.
Harms. Fragment harms and systematic safety assessment not established in accessible abstract.
Limits. Diabetic-mouse/rat wound findings and diabetic keratinocyte migration null results concern parent TB4; do not assign them to this fragment. Fragment-specific sample size, delivery route and terminal chemistry remain unverified in this excerpt.
Preparation: Synthetic LKKTETQ; terminal chemistry and commercial equivalence unverified. Route: Fragment route not established in accessible original abstract.
Read original source ↗Editorial review 2026-10-10. Clinician review pending.